<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): October 30, 2008</B>


<P style="font-size: 18pt" align="center"><B>INTEGRA LIFESCIENCES HOLDINGS
CORPORATION<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-26224</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>51-0317849</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>311 Enterprise
Drive<BR>
Plainsboro, NJ <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>08536</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(609) 275-0500</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>Not
Applicable<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>ITEM 2.03. CREATION OF A DIRECT
FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF
A REGISTRANT.</B>

<P style="font-size: 10pt" align="left">On October&nbsp;30, 2008, Integra
LifeSciences Holdings Corporation, a Delaware corporation (the
&#8220;Company&#8221;), borrowed $60 million under its senior secured revolving
credit facility for general corporate purposes. As a result of this borrowing,
the Company has $260&nbsp;million of outstanding borrowings under its credit
facility as of the date of this filing.

<P style="font-size: 10pt" align="left">The outstanding borrowings have
one-month interest periods. The weighted average interest rate of the
outstanding borrowings is approximately 4.0%.

<P style="font-size: 10pt" align="left">The credit facility requires the
Company to maintain various financial covenants, including leverage ratios, a
minimum fixed charge coverage ratio and a minimum liquidity ratio. The credit
facility also contains customary affirmative and negative covenants, including
those that limit the Company&#8217;s and its subsidiaries&#8217; ability to
incur additional debt, incur liens, make investments, enter into mergers and
acquisitions, liquidate or dissolve, sell or dispose of assets, repurchase
stock and pay dividends, engage in transactions with affiliates, engage in
certain lines of business and enter into sale and leaseback transactions. In
addition, as previously disclosed, the Company obtained waivers from the
lenders under the credit facility relating to: (i)&nbsp;representations
regarding the Company&#8217;s disclosed material weaknesses; and (ii)&nbsp;the
calculation of the consolidated fixed charge ratio under the credit agreement
as it relates to tax recapture payments made by the Company in connection with
the repayment of certain indebtedness.

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt" align="left">Pursuant to the requirements of the
Securities Exchange Act of 1934, as amended, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly
authorized.

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="50%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>INTEGRA LIFESCIENCES HOLDINGS CORPORATION</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Date: November&nbsp;5, 2008

<P style="margin-top: -11pt; font-size: 10pt; margin-left: 51%"
align="left">By: <U><B>/</B>s/ John B. Henneman,
III</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<BR>
John B. Henneman, III <BR>
Title: Executive Vice President,<BR>Finance and Administration,<BR>and Chief Financial Officer

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD></TD>
 </TR>

</TABLE>




<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c76769e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 7941}]
{"company-data": {"conformed-name": "INTEGRA LIFESCIENCES HOLDINGS CORP", "cik": "0000917520", "assigned-sic": "3826", "irs-number": "510317849", "state-of-incorporation": "DE", "fiscal-year-end": "1206"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26224", "film-number": "081164292"}, "business-address": {"street1": "311 C ENTERPRISE DRIVE", "city": "PLAINSBORO", "state": "NJ", "zip": "08536", "phone": "6092750500"}, "mail-address": {"street1": "311 C ENTERPRISE DRIVE", "city": "PLAINSBORO", "state": "NJ", "zip": "08536"}, "former-company": {"former-conformed-name": "INTEGRA LIFESCIENCES CORP", "date-changed": "19950614"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): October 30, 2008
INTEGRA LIFESCIENCES HOLDINGS
CORPORATION
(Exact name of registrant as
specified in its charter)
Delaware
0-26224
51-0317849
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
311 Enterprise
Drive
Plainsboro, NJ
08536
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(609) 275-0500
Not
Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.03. CREATION OF A DIRECT
FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF
A REGISTRANT.
On October 30, 2008, Integra
LifeSciences Holdings Corporation, a Delaware corporation (the
"Company"), borrowed $60 million under its senior secured revolving
credit facility for general corporate purposes. As a result of this borrowing,
the Company has $260 million of outstanding borrowings under its credit
facility as of the date of this filing.
The outstanding borrowings have
one-month interest periods. The weighted average interest rate of the
outstanding borrowings is approximately 4.0%.
The credit facility requires the
Company to maintain various financial covenants, including leverage ratios, a
minimum fixed charge coverage ratio and a minimum liquidity ratio. The credit
facility also contains customary affirmative and negative covenants, including
those that limit the Company's and its subsidiaries' ability to
incur additional debt, incur liens, make investments, enter into mergers and
acquisitions, liquidate or dissolve, sell or dispose of assets, repurchase
stock and pay dividends, engage in transactions with affiliates, engage in
certain lines of business and enter into sale and leaseback transactions. In
addition, as previously disclosed, the Company obtained waivers from the
lenders under the credit facility relating to: (i) representations
regarding the Company's disclosed material weaknesses; and (ii) the
calculation of the consolidated fixed charge ratio under the credit agreement
as it relates to tax recapture payments made by the Company in connection with
the repayment of certain indebtedness.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, as amended, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly
authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: November 5, 2008
By:
/
s/ John B. Henneman,
III
John B. Henneman, III
Title: Executive Vice President,
Finance and Administration,
and Chief Financial Officer